Peptides that home to tumor lymphatic vasculature and...

Details Peptides that home to tumor lymphatic vasculature and... Peptides that home to tumor lymphatic vasculature and...

2007-03-20

2007-03-20

Siew, Jeffrey (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S329000, C530S317000

Reexamination Certificate

active

10290385

ABSTRACT:
The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature.

REFERENCES:
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5789542 (1998-08-01), McLaughlin et al.
patent: 0 927 045 (1999-07-01), None
patent: WO 97/10507 (1997-03-01), None
patent: WO99/13329 (1999-03-01), None
patent: WO 00/42973 (2000-07-01), None
patent: WO 00/00824 (2002-01-01), None
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990).
Lazar et al. ( Mol. Cell Biol. 8:1247-1252, 1998).
Wen et al. (Proc. Natl. Acad. Sci. U.S.A. 98: 4622-4627, 2001).
Breiteneder-Geleff et al., “Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium,”American J. of Pathology154:385-394 (1999).
Alvarez-Bravo et al., “Novel synthetic antimicrobial peptides effective against methicillin-resistantStaphylococcus aureus,” Biochem. J.302:535-538 (1994).
Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,”Science279:377-380 (1998).
Bessalle et al., “All-D-magainin: Chirality, antimicrobial activity and proteolytic resistance,”FEBS Lett274:151-155 (1990).
Blondelle and Houghten, “Design of Model Amphipathic Peptides Having Potent Antimicrobial Activities,”Biochemistry31:12688-12694 (1992).
Borgstrom et al., “Importance of VEGF for breast cancer angiogenesisin vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin,”Anticancer Res.19:4203-4214 (1999).
Chan et al., “Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer,”J. Clin. Oncol.17:2341-2354 (1999).
Crown, “The platinum agents: A role in breast cancer treatment,”Seminars in Oncology28:28-37 (2001).
Ebata et al., “Desmoplakin as a specific marker of lymphatic vessels,”Microvasc. Res.61:40-48 (2001).
Fisher et al., “Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study,”J. Natl. Cancer Instit.90:1371-1388 (1998).
Fitzpatrick and Garnett, “Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers,”Anticancer Drug Des.10:1-9 (1995).
Fukuda et al., “Anatomic distribution of intraprostatic lymphatics: Implications for the lymphatic spread of prostate cancer-a preliminary study,”Prostate44:322-327 (2000).
Gallouzi and Steitz, “Delineation of mRNA Export Pathways by the Use of Cell-Permeable Peptides,”Science294:1895-1901 (2001).
GenBank Accession No. NP 039684.1.
GenBank Accession No. AAB00335.1.
GenBank Accession No. AAG32611.1.
GenBank Accession No. T28529.
GenBank Accession No. NP 073464.
Harris et al., “Cancer of the Breast,” In:Cancer: Principles and Practice of Oncology, 4th ed., Chapter 40 (eds. DeVita, Jr., et al. ; J.P. Lippincott) (1993).
Karkkainen and Petrova, “Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis,”Oncogene19:5598-5605 (2000).
Maloy and Kari, “Structure-activity studies on magainins and other host defense peptides,”Biopolymers37:105-122 (1995).
Mancheno et al., “A peptide of nine amino acid residues from α-sarcin cytotoxin is a membrane-perturbing structure,”J. Peptide Res.51:142-148 (1998).
Paridaens et al., “Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over,”J. Clin. Oncol.18:724-733 (2000).
Pasqualini and Ruoslahti, “Organ targetingin vivousing phage display peptide libraries,”Nature380:364-366 (1996).
Prevo et al., “Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium,”J. Biol. Chem.276:19420-19430 (2001).
Rajotte et al., “Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display,”J. Clin. Inv.102:430-437 (1998).
Rusinko et al., “Using CONCORD to Construct a Large Database of Three-Dimensional Coordinates from Connection Tables,”J. Chem. Inf. Comput. Sci.29:251-255 (1989).
Saberwal and Nagaraj, “Cell-lytic and antibacterial peptides that act by perturbing the barrier function of membranes: Facets of their conformational features, structure-function correlations and membrane-perturbing abilities,”Biochim. Biophys. Acta1197:109-131 (1994).
Schneider et al., “Lymphangioblasts in the avian wing bud,”Dev. Dyn.216:311-319 (1999).
Schwarze et al., “In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse,”Science285:1569-1572 (1999).
Skobe et al., “Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis,”Nature Medicine7:192-198 (2001).
Sidhu et al., “Phage display for selection of novel binding peptides,”Methods Enzym.328:333-363 (2000).
Stacker et al., “VEGF-D promotes the metastatic spread of tumor cells via the lymphatics,”Nature Medicine7:186-191 (2001).
Stewart and Ratain, “Topoisomerase Interactive Agents,”Cancer: Principles and Practice of Oncology, 5th ed., eds. DeVita, Jr., et al., Chapter 19, pp. 452-467 (1997).
Veikkola et al., “Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice,”EMBO J.20:1223-1231 (2001).
Wender et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters,”Proc. Natl. Acad. Sci.97:13003-13008 (2000).
White et al., “Antibody-targeted immunotherapy for treatment of malignancy,”Annu. Rev. Med.52:125-145 (2001).
Wigle and Oliver, “Proxlfunction is required for the development of the murine lymphatic system,”Cell98:769-778 (1999).
Aoki et al., “Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif,”Cancer Gene. Ther.8:783-787 (2001).
Curnis et al., “Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)”Nat. Biotechnol.18: 1185-1190 (2000).
Laakkonen et al., “A tumor-homing peptide with a targeting specificity related to lymphatic vessels,”Nat. Med.8:751-755 (2002).
Pasqualini et al., “Organ targeting in vivo using phage display peptide libraries,”Nature380: 364-366 (1996).
Trepel et al., “Molecular adaptors for vascular-targeted adenoviral gene delivery,”Hum. Gene. Ther.11:1971-1981 (2001).
Brown et al. “A novel approach for the identification of unique tumor vasculature binding peptides using an E coli peptide display library,”Ann Surg Oncol., Dec. 7(10):743-749 (2000).
Burg et al. “NG2 proteoglycan-binding peptides target tumor neovasculature,”Cancer Res., 59:2869-2874 (1999).
Cortese et al. “Identification of peptides binding to IgG in the CSF of multiple sclerosis patients,”Mult Scler, 4:31-36 (1998).
Dekker et al. “Substrate specificity of the integral membrane protease OmpT determined by spatially addressed peptide libraries,”Biochemistry, 40(6):1694-1701 (2001).
Ellerby et al. “ Anti-cancer activity of targeted pro-apoptotic peptides,”Nat. Med., 5(9):1032-1038 (1999).
Nelson et al. “Murine epidermal growth factor peptide (33-42) binds to a YIGSR-specific laminin receptor on

Affiliated with

Also associated with

Rating

Peptides that home to tumor lymphatic vasculature and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides that home to tumor lymphatic vasculature and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides that home to tumor lymphatic vasculature and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3781331